Project to support adoption of the io® rapid diagnostic platform into UK sexual health clinics

Bath, UK, 14 August, 2017. Atlas Genetics Ltd., the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces that it has been awarded a two year Innovate UK phase II contract to expand the Sexually Transmitted Infection (STI) test menu for the io® rapid diagnostic platform and support its adoption into UK sexual health clinics.

Valued at approximately £2m, this contract will bring together Atlas Genetics, Aquarius Population Health (a leading independent health economics consultancy) and the Applied Diagnostic Research and Evaluation Unit (ADREU) at St George’s University of London.

This collaboration will enable further research into diagnostic pathways within sexual health and the benefits of the introduction of POC testing, to be demonstrated by the design of a digital value proposition tool. The project will also include the evaluation of the io® rapid diagnostic platform in several UK sexual health clinics and assist the development of Atlas Genetics’ Multi-STI (io® MSTI) test ahead of clinical trials. io® MSTI is a novel multi-pathogen test for Chlamydia trachomatis, Neisseria gonorrhoea, Trichomonas vaginalis and Mycoplasma genitalium.

The io® system is a highly innovative molecular diagnostic platform for the ultra-rapid diagnosis of a broad range of infectious diseases. The system offers a sample-to-answer time of 30 minutes making it possible to carry out infectious disease tests in primary care clinics and physicians’ offices that are as accurate as those carried out in hospital laboratories.

Dr John Clarkson, Chief Executive Officer of Atlas Genetics, said: “We are delighted to have been selected for this substantial follow-on contract. The work being done by this collaboration will enable us to better understand how best to integrate our io® system into UK sexual health clinical practice. Innovate UK’s commitment to introducing new, pioneering approaches to healthcare validates both our technology and our leading role in molecular diagnostics.”

Dr Elisabeth Adams, Managing Director of Aquarius Population Health commented: “We are very excited to collaborate on this Innovate UK funded project. Together with Atlas Genetics, we are developing an innovative digital value proposition tool which we believe will help sexual health clinics in their commissioning and adoption of io® rapid diagnostic platform.”

Dr Tariq Sadiq, Director of the Applied Diagnostic and Research Evaluation Unit at St George’s University of London, added: “This is a highly exciting and innovative approach to better understand and overcome the often complex and substantial challenges to getting cutting-edge technology adopted into the NHS. We believe that there are real benefits to using the io® rapid diagnostic platform as patients will be able to receive the appropriate treatment immediately and thereby reduce onward transmission, and ultimately save the NHS time and money."

Financing global launch and menu development of Atlas Genetics’ io® molecular testing system

Bath, UK, 23 January, 2017. Atlas Genetics Ltd., the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces completion of its Series D financing, raising $35 million from a syndicate including all Series C Investors and one new investor, Wondfo Biotech. Development of the Atlas Genetics io® system has been completed with the successful CE marking of the Chlamydia trachomatis (CT) test announced in February 2016.  This new Series D equity issue will finance the clinical trials and commercial launch of a second test, for detection of both Chlamydia and Gonorrhoea, planned for regulatory approvals in the US around the end of 2017, as well as further development of additional diagnostics menu.  The financing also provides funding to expand cartridge manufacturing capacity at Bespak, Atlas Genetics’ cartridge manufacturing partner.

The io® system is a highly novel molecular diagnostic platform for the ultra-rapid diagnosis of a broad range of infectious diseases.  The system offers a sample-to-answer time of under 30 minutes making it possible to carry out infectious disease tests in primary care clinics and physicians’ offices that are as accurate as those carried out in hospital laboratories.  It is based on a patent-protected electrochemical sensor technology that combines speed, accuracy and low manufacturing costs.  The fully integrated cartridge contains all reagents and is designed to receive an unprocessed clinical specimen. Each cartridge can detect up to 24 different genetic targets from a single patient sample.  Wondfo Biotech, the new investor, is a well-established Chinese in vitro diagnostic company, with over 1,000 employees based in Guangzhou, Guangdong Province, that develops and manufactures a broad range of diagnostic assays including several POC tests.  Existing investors include Novartis Venture Funds, Consort Medical plc, Johnson & Johnson Innovation - JJDC, Inc., LSP, BB Biotech Ventures, RMI Partners and Technology Venture Partners.  This new financing follows on from the previously announced Series C fundraising of $20 million in January 2015.

Dr John Clarkson, Chief Executive Officer of Atlas Genetics, commented: “We have continued to make excellent progress and are delighted to have raised significant funds to allow us to complete clinical trials, registration and launch in Europe and the US of our flagship product, a combined CT/NG (Chlamydia / Gonorrhoea) test, as well as to further our menu development.  Our system will enable physicians to test and treat patients immediately for what can be distressing conditions.  Immediate treatment enables better antibiotic stewardship and prevents onward transmission, which will help to reduce the associated financial burdens that these infections place on our healthcare systems.  We believe that Atlas Genetics is poised to become a world leader in POC molecular diagnostics and we plan to roll-out new assays in a range of clinical areas over the next two years and beyond.”